EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR IN PEOPLE WITH CHRONIC HEPATITIS C VIRUS INFECTION AND RECENT INJECTING DRUG USE: THE SIMPLIFY STUDY

Grebely J1, Dalgard O2, Conway B3, Cunningham E1, Bruggmann P4, Hajarizadeh B1, Amin J1, Marks P1, Quiene S1, Applegate TL1, Swan T5, Byrne J6, Lacalamita M7, Dunlop A8, Bruneau J9, Hellard ME10, Matthews GV11,11, Powis J12, Shaw D13, Thurnheer MC7, Weltman M14, Kronborg I15, Cooper C16, Feld JJ17, Fraser C16, Litwin A19, Dillon J20, Read P21, Gane E22 and Dore GJ1,11 on behalf of the SIMPLIFY Study Group

1The Kirby Institute, UNSW Sydney, Sydney, Australia, 2Akershus University Hospital, Oslo, Norway, 3Vancouver Infectious Diseases Center, Vancouver, Canada, 4Arud Centre for Addiction Medicine, Zurich, Switzerland, 5Médecins Sans Frontières, New York, United States, 6Australian Injecting & Illicit Drug Users League, 7Poliklinik für Infektiologie, Inselspital, Bern, Switzerland, 8Newcastle Pharmacotherapy Service, Newcastle, Australia, 9Centre Hospitalier de l'Université de Montréal, Canada, 10The Burnet Institute, Melbourne, Australia, 11St Vincent's Hospital, Sydney Australia, 12South Riverdale Community Health Centre, Toronto, Canada, 13Royal Adelaide Hospital, Adelaide, Australia, 14Nepean Hospital, Penrith, Australia, 15Footscray Hospital, Footscray, Australia, 16Ottawa Hospital Research Institute, Ottawa, Canada, 17Toronto General Hospital, Toronto, 18Coolaid Community Health Centre, Victoria, Canada, 19Montefiore Medical Centre, New York, United States, 20Ninewells Hospital, Dundee, United Kingdom, 21Kirketon Road Centre, Sydney, Australia, 22Auckland Hospital, Auckland, New Zealand.

Introduction: Interferon-free direct-acting antiviral therapy (DAA) is safe and effective in people with hepatitis C virus (HCV) receiving stable opioid substitution therapy (OST), but there are little data among recent people who inject drugs (PWID). Improved evidence of DAA outcomes among recent PWID is crucial for elimination efforts, given the potential impact of HCV treatment as prevention. The aim of this study was to evaluate the efficacy and safety of sofosbuvir/velpatasvir for chronic HCV among recent PWID.

Methods: SIMPLIFY is an international open-label study that recruited participants with recent injecting drug use (previous six months) and chronic HCV genotype (G) 1-6 infection between March and October, 2016 in seven countries (19 sites). Participants received sofosbuvir/velpatasvir daily administered in a one-week electronic blister pack (records the time and date of each dose) for 12 weeks. The primary endpoint was sustained virological response at 12 weeks (SVR) after the end of therapy.

Results: Of 103 participants who initiated treatment (mean age 47 years; 72% male; 9% cirrhosis), 35% had HCV G1, 5% G2, 58% G3, and 2% G4. At screening, 57% were receiving OST, with 74% injecting in the past month, 48% at least once a week. Overall, 96% (99/103) completed treatment. There were four discontinuations (loss to follow-up, n=3; overdose death, n=1). End of treatment response (ETR) was 96% (99/103). Overall, two participants with an ETR did not have SVR12 [loss to follow-up, n=1; virological relapse/reinfection, n=1 (undergoing sequencing to confirm)]. In intent-to-treat analyses among all participants, SVR12 was 94% (97/103).

Conclusion: In this study of once-daily sofosbuvir/velpatasvir among people with recent injecting drug use and chronic HCV, high treatment completion, and SVR were observed, with no cases of virological failure and one case of virological relapse/reinfection. This supports DAA therapy in recent PWID, a key population for HCV elimination strategies.